Abstract: The invention provides compositions and methods for providing a cardioprotective effect in a subject. Specifically, the invention relates to compositions and methods for treating cardiovascular ailments, such as compositions and methods for attenuating or ameliorating the development of cardiac contractile dysfunction, myocardial fibrosis or maladaptive remodeling in a subject having or having had a myocardial infarction (MI) or at risk of having a myocardial infarction by administering a retinoic acid receptor-beta (RAR?) agonist.

Abstract: The printing machine comprising at least one protective replaceable self-adhesive film (1) at least for the principal surfaces most affected by splashes of ink and/or varnish and by the normal accumulation of dirt.

Abstract: An underblanket of the blanket of a blanket cylinder of a printing press, particularly of the offset type, consists of a multilayer structure comprising a first layer comprising at least one polyurethane-based material, and at least a second layer comprising at least one polyurethane-based material, which is different from the one forming said first layer, and directly joined with said first layer by exploiting the intrinsic chemical/physical compatibility.

Abstract: The printing machine comprising at least one protective replaceable self-adhesive film (1) at least for the principal surfaces most affected by splashes of ink and/or varnish and by the normal accumulation of dirt.

Abstract: An underblanket of the blanket of a blanket cylinder of a printing press, particularly of the offset type, consists of a multilayer structure comprising a first layer comprising at least one polyurethane-based material, and at least a second layer comprising at least one polyurethane-based material, which is different from the one forming said first layer, and directly joined with said first layer by exploiting the intrinsic chemical/physical compatibility.

Abstract: The coating for a printing machine blanket cylinder, comprises a multilayer structure comprising a printing blanket layer of the type suitable for the type of printing machine and an underlying elastomer layer having such physical/chemical characteristics that the body of the elastomer layer has self-levelling capacities and such thickness that combined with the thickness of the printing blanket layer it allows to maintain the desired overall thickness for the multilayer structure, a first face of the elastomer layer being integrally joined with the printing blanket layer, and a second face of the elastomer layer having a direct adhesion capacity and without requiring the interposition of additional adhesive products with the cylinder capable of adhering both in static and dynamic conditions at least sufficient to guarantee the maintenance of a perfect adhesion against the cylinder on one side and an easy removal from the same on the other.

Abstract: The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that involve inhibiting the synthesis and/or release of renin from mast cells and/or inhibiting the activity of renin after release from mast cells. The methods of the invention can also involve inhibiting elements of the local renin-angiotensin system (e.g.

Abstract: The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that involve inhibiting the synthesis and/or release of renin from mast cells and/or inhibiting the activity of renin after release from mast cells. The methods of the invention can also involve inhibiting elements of the local renin-angiotensin system (e.g. inhibiting ACE and angiotensin II receptors), thereby inhibiting angiotensin II produced locally from mast-cell-derived renin.

Abstract: A self-levelling under-packing for printing presses, in particular offset presses, includes at least one polyester-based layer and at least one polyurethane elastomer layer joined inseparably together. The polyester-based layer may be between 50 ?m and 350 ?m and the polyurethane elastomer layer may be between 20 ?m and 1000 ?m. The polyester-based layer may be adhesive-coated on one side, in which case the thickness, including the adhesive, may be between 40 and 100 ?m, with the adhesive thickness not exceeding about 5 ?m.

Abstract: The invention relates to the discovery that renin is present in mast cells and can act in a localized manner to initiate and/or exacerbate a number of conditions. Thus, the invention provides methods for treating cardiac, vascular, lung, liver, cervical, intestinal, muscle, pancreatic, brain, kidney, skin and other conditions that involve inhibiting the synthesis and/or release of renin from mast cells and/or inhibiting the activity of renin after release from mast cells. The methods of the invention can also involve inhibiting elements of the local renin-angiotensin system (e.g.

Abstract: A self-levelling under-packing for printing presses, in particular offset presses, includes at least one polyester-based layer and at least one polyurethane elastomer layer joined inseparably together. The polyester-based layer may be between 50 ?m and 350 ?m and the polyurethane elastomer layer may be between 20 ?m and 1000 ?m. The polyester-based layer may be adhesive-coated on one side, in which case the thickness, including the adhesive, may be between 40 and 100 ?m, with the adhesive thickness not exceeding about 5 ?m.

Abstract: The self-levelling under-packing for printing presses, in particular offset presses, comprises at least one polyester-based layer and at least one polyurethane elastomer layer joined inseparably together.

Abstract: The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H3 Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Nai) by inhibiting the Na+/H+ exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca2+ channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H3 Receptor agonist with a pharmaceutical carrier.

Abstract: Sheets of rubber-coated fabric are mounted on the cylinders of offset printing presses. An under-packing formed from the combination of an optional flexible supporting sheet and a plurality of flexible packing sheets is interposed between the cylinder surface and the rubber-coated fabric to obtain a predetermined total thickness which varies for different types of printing presses. The thickness of the under-packing is equal to a predetermined maximum thickness. The thickness of the sheets of the under-packing is chosen such that by removing one or more packing sheets from the under-packing, the desired thickness for any specific case can be approximated. A face of each packing sheet which faces inwards, with the exception of the face of the innermost sheet or the supporting sheet if the supporting sheet is the innermost sheet, is treated with an adhesive which, while maintaining the sheets united, enables them to be separated from each other.

Abstract: The present invention provides a method for treating a human suffering from myocardial ischemia, cardiac arrhythmia, or both. The method comprises administering locally to a heart of a human an effective amount of an enzyme inhibitor that inhibits formation of angiotensin II in the heart. The invention also provides an isolated human renin of about 32-36 kDa.

Abstract: Sheets of rubber-coated fabric are mounted on the cylinders of offset printing presses. An under-packing formed from the combination of a flexible supporting sheet (12), which may however be dispensed with, and a multiplicity of flexible graded sheets (14) has to be interposed between the cylinder surface and the rubber-coated fabric to obtain a predetermined total thickness which varies as the type of printing press varies. The total thickness of the universal under-packing (10) according to the invention is equal to a predetermined maximum thickness. The thickness of the sheets (12, 14) of the universal under-packing (10) is chosen such that by removing from the universal under-packing (10) one or more graded sheets (14), the thickness which has to be obtained for any specific case can be sufficiently approximated to.

Abstract: The invention provides a method for reducing cardiac dysfunctions in a human. The method comprises administration to the human of an effective amount of a selective histamine H3 Receptor agonist. In one embodiment, the method comprises limiting the accumulation of intracellular sodium (Nai) by inhibiting the Na+/H+ exchanger activity in the human having a cardiac dysfunction, or a predisposition to a cardiac dysfunction. In another embodiment the method comprises inhibiting the N-type Ca2+ channel to modulate the concentration of intracellular calcium. The invention also provides a pharmaceutical composition that includes a selective histamine H3 Receptor agonist with a pharmaceutical carrier.

Abstract: A method for prophylaxis or treatment of an animal for systemic hypotension induced by internal nitrogen oxide production. The method involves administering a therapeutically effective amount of certain arginine derivatives to inhibit nitrogen oxide formation from arginine. Preferably N.sup.G -substituted arginine or an N.sup.G,N.sup.G -disubstituted arginine (having at least one hydrogen on a terminal guanidino amino group replaced by another atomic species) is administered to an animal possibly developing or already having such induced systemic hypotension. The arginine derivatives are preferably of the L configuration and include pharmaceutically acceptable addition salts. Prophylaxis or treatment of systemic hypotension in a patient which has been induced by chemotherapeutic treatment with biologic response modifiers such as tumor necrosis factor or interleukin-2 may be accomplished. Treatment of an animal for systemic hypotension induced by endotoxin, i.e.

Abstract: Reducing plasma levels of endogenous arginine by parenteral administration of arginine depleting agent limits nitric oxide formation and results in blood pressure increase. Preferably arginase is administered intravenously to raise blood pressure. The arginine depleting agent can be administered in conjunction with arginine antagonists to potentiate the effect of these. The arginine depleting agent can be used concurrently with .alpha..sub.1 adrenergic agonists in treating systemic hypotension caused by induced production of nitric oxide, to restore vascular contractile sensitivity to the effect of the .alpha..sub.1 adrenergic agonists. Duration of action and avoidance of antigenicity may be obtained by use in conjunction with a carrier or modifier.

Abstract: A method for treatment of an animal for systemic hypotension induced by internal nitric oxide production caused by endotoxin or cytokines. The method involves administering an .alpha..sub.1 adrenergic agonist and an amount of an inhibitor of nitric oxide formation from argiResearch relating to the development of this invention was supported by the United States Public Health Service grants which gives the United States government certain rights to use of the present invention.